Parkinson's Disease Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amneal Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Parkinson's Disease pipeline constitutes 140+ key companies continuously working towards developing 150+ Parkinson's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Parkinson's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson's Disease Market.

The Parkinson's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Parkinson's Disease Pipeline Report: https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Parkinson's Disease treatment therapies with a considerable amount of success over the years.
• Parkinson's Disease companies working in the treatment market are FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others, are developing therapies for the Parkinson's Disease treatment
• Emerging Parkinson's Disease therapies in the different phases of clinical trials are- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others are expected to have a significant impact on the Parkinson's Disease market in the coming years.
• In October 2024, Adaptive Research, a clinical trial site organization focused on making clinical trials more accessible, announced its involvement in a pioneering decentralized study for Parkinson's Disease sponsored by PhotoPharmics Inc. The California Movement Disorders Center, part of Adaptive Research's network, will be a site for PhotoPharmics' LIGHT-PD trial, which aims to evaluate the effectiveness of Celeste® Specialized Phototherapy in treating Parkinson's symptoms.
• In September 2024, AbbVie's recently acquired Parkinson's disease treatment, tavapadon, demonstrated a significant reduction in disease burden in a Phase III trial. The TEMPO-1 trial (NCT04201093) assessed two daily doses of tavapadon (5mg and 15mg) and successfully met its primary endpoint. Both dosage groups outperformed the placebo in reducing disease burden at week 26, as evaluated by a combined score from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
• In December 2023, Gain Therapeutics, a biotechnology company situated in the United States, has released preclinical findings showcasing the promise of small molecule allosteric regulators in addressing beta-galactosidase-1 (GLB1)-related lysosomal storage disorders, including GM1 gangliosidosis.
• In December 2023, Vanqua Bio disclosed plans to commence clinical trials in the first quarter of 2024, evaluating the investigational drug VQ-101 as a potential treatment for Parkinson's disease linked to GBA1 mutations.

Parkinson's Disease Overview

Parkinson's disease is a progressive nervous system disorder that affects movement. It develops when there is a gradual loss of certain nerve cells in the brain that produce dopamine, a chemical messenger responsible for smooth and coordinated muscle movements. As dopamine levels decrease, individuals with Parkinson's disease experience difficulties with movement control.

Get a Free Sample PDF Report to know more about Parkinson's Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Parkinson's Disease Drugs Under Different Phases of Clinical Development Include:
• KM-819: FAScinate Therapeutics
• Prasinezumab: Hoffmann-La Roche
• P2B001: Pharma Two B Ltd.
• NPT1220-478: Neuropore Therapies, Inc.
• Dapansutrile: Olatec Therapeutics
• UCB7853: UCB Biopharma
• UB-312: Vaxxinity
• Emrusolmin: Modag
• PT320: Peptron
• KDT-3594: Kissei Pharmaceutical
• Tavapadon: Cerevel Therapeutics

Parkinson's Disease Route of Administration
Parkinson's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Parkinson's Disease Molecule Type
Parkinson's Disease Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Parkinson's Disease Pipeline Therapeutics Assessment
• Parkinson's Disease Assessment by Product Type
• Parkinson's Disease By Stage and Product Type
• Parkinson's Disease Assessment by Route of Administration
• Parkinson's Disease By Stage and Route of Administration
• Parkinson's Disease Assessment by Molecule Type
• Parkinson's Disease by Stage and Molecule Type

DelveInsight's Parkinson's Disease Report covers around 150+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Parkinson's Disease product details are provided in the report. Download the Parkinson's Disease pipeline report to learn more about the emerging Parkinson's Disease therapies
https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Parkinson's Disease Therapeutics Market include:
Key companies developing therapies for Parkinson's Disease are - Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others.

Parkinson's Disease Pipeline Analysis:
The Parkinson's Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson's Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's Disease Treatment.
• Parkinson's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Parkinson's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Parkinson's Disease drugs and therapies
https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Parkinson's Disease Pipeline Market Drivers
• Increasing prevalence of Parkinson's Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson's Disease Market.

Parkinson's Disease Pipeline Market Barriers
• However, lack of awareness and delayed diagnosis, side effects associated with Parkinson's disease treatment drugs and other factors are creating obstacles in the Parkinson's Disease Market growth.

Scope of Parkinson's Disease Pipeline Drug Insight
• Coverage: Global
• Key Parkinson's Disease Companies: FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others
• Key Parkinson's Disease Therapies: KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others
• Parkinson's Disease Therapeutic Assessment: Parkinson's Disease current marketed and Parkinson's Disease emerging therapies
• Parkinson's Disease Market Dynamics: Parkinson's Disease market drivers and Parkinson's Disease market barriers

Request for Sample PDF Report for Parkinson's Disease Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Parkinson's Disease Report Introduction
2. Parkinson's Disease Executive Summary
3. Parkinson's Disease Overview
4. Parkinson's Disease- Analytical Perspective In-depth Commercial Assessment
5. Parkinson's Disease Pipeline Therapeutics
6. Parkinson's Disease Late Stage Products (Phase II/III)
7. Parkinson's Disease Mid Stage Products (Phase II)
8. Parkinson's Disease Early Stage Products (Phase I)
9. Parkinson's Disease Preclinical Stage Products
10. Parkinson's Disease Therapeutics Assessment
11. Parkinson's Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Parkinson's Disease Key Companies
14. Parkinson's Disease Key Products
15. Parkinson's Disease Unmet Needs
16 . Parkinson's Disease Market Drivers and Barriers
17. Parkinson's Disease Future Perspectives and Conclusion
18. Parkinson's Disease Analyst Views
19. Appendix
20. About DelveInsight

Latest Reports:
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.